Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 28 Triple Negative Breast Neoplasms 12 Prostatic Neoplasms 12 Ovarian Neoplasms 10 Neoplasms 10 Neoplasm Metastasis 9 Leukemia, Myeloid, Acute 5 Fallopian Tube Neoplasms 5 Small Cell Lung Carcinoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Pancreatic Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

pembrolizumab 76 Gemcitabine 48 Nivolumab 41 Cisplatin 35 atezolizumab 34 Carboplatin 27 avelumab 25 enfortumab vedotin 23 Docetaxel 22 Magnetic Resonance Spectroscopy 17 Paclitaxel 15 Ipilimumab 15 Mitomycin 14 Specimen Handling 12 durvalumab 10 toripalimab 9 sacituzumab govitecan 9 Pemetrexed 8 vinflunine 7 cabozantinib 7 Taxes 7 Injections 6 Cyclophosphamide 6 Bevacizumab 6 tislelizumab 5 pemigatinib 5 Standard of Care 5 Fluorodeoxyglucose F18 5 Biopsy 5 lenvatinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡